310 related articles for article (PubMed ID: 14593715)
1. The development of protein farnesyltransferase inhibitors as signaling-based anticancer agents.
Ohkanda J; Blaskovich MA; Sebti SM; Hamilton AD
Prog Cell Cycle Res; 2003; 5():211-7. PubMed ID: 14593715
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of Ras prenylation: a signaling target for novel anti-cancer drug design.
Lerner EC; Hamilton AD; Sebti SM
Anticancer Drug Des; 1997 Jun; 12(4):229-38. PubMed ID: 9199657
[TBL] [Abstract][Full Text] [Related]
3. Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development.
Rowinsky EK; Windle JJ; Von Hoff DD
J Clin Oncol; 1999 Nov; 17(11):3631-52. PubMed ID: 10550163
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological inhibitors of the ERK signaling pathway: application as anticancer drugs.
Kohno M; Pouyssegur J
Prog Cell Cycle Res; 2003; 5():219-24. PubMed ID: 14593716
[TBL] [Abstract][Full Text] [Related]
5. The molecular perspective: protein farnesyltransferase.
Goodsell DS
Stem Cells; 2004; 22(1):119-20. PubMed ID: 14688398
[No Abstract] [Full Text] [Related]
6. C-terminal modifications of histidyl-N-benzylglycinamides to give improved inhibition of Ras farnesyltransferase, cellular activity, and anticancer activity in mice.
McNamara DJ; Dobrusin E; Leonard DM; Shuler KR; Kaltenbronn JS; Quin J; Bur S; Thomas CE; Doherty AM; Scholten JD; Zimmerman KK; Gibbs BS; Gowan RC; Latash MP; Leopold WR; Przybranowski SA; Sebolt-Leopold JS
J Med Chem; 1997 Oct; 40(21):3319-22. PubMed ID: 9341905
[No Abstract] [Full Text] [Related]
7. Ras farnesyltransferase: a new therapeutic target.
Leonard DM
J Med Chem; 1997 Sep; 40(19):2971-90. PubMed ID: 9301658
[No Abstract] [Full Text] [Related]
8. Farnesyltransferase inhibitors as anticancer agents: current status.
Zhu K; Hamilton AD; Sebti SM
Curr Opin Investig Drugs; 2003 Dec; 4(12):1428-35. PubMed ID: 14763128
[TBL] [Abstract][Full Text] [Related]
9. Farnesyltransferase as a target for anticancer drug design.
Qian Y; Sebti SM; Hamilton AD
Biopolymers; 1997; 43(1):25-41. PubMed ID: 9174410
[TBL] [Abstract][Full Text] [Related]
10. [Inhibitors of Ras farnesylation: tomorrow's anticancer agents?].
Perrin D; Halazy S; Hill B
Bull Cancer; 1997 Jun; 84(6):635-42. PubMed ID: 9295868
[TBL] [Abstract][Full Text] [Related]
11. Ras farnesyltransferase inhibition: a novel and safe approach for cancer chemotherapy.
Nammi S; Lodagala DS
Acta Pharmacol Sin; 2000 May; 21(5):396-404. PubMed ID: 11324435
[TBL] [Abstract][Full Text] [Related]
12. [Signal transduction inhibitor].
Ueda Y; Saijo N
Gan To Kagaku Ryoho; 2001 May; 28(5):591-600. PubMed ID: 11383206
[TBL] [Abstract][Full Text] [Related]
13. Potent and selective non-cysteine-containing inhibitors of protein farnesyltransferase.
Augeri DJ; O'Connor SJ; Janowick D; Szczepankiewicz B; Sullivan G; Larsen J; Kalvin D; Cohen J; Devine E; Zhang H; Cherian S; Saeed B; Ng SC; Rosenberg S
J Med Chem; 1998 Oct; 41(22):4288-300. PubMed ID: 9784104
[TBL] [Abstract][Full Text] [Related]
14. Farnesyltransferase inhibitors.
Adjei AA
Cancer Chemother Biol Response Modif; 2002; 20():151-67. PubMed ID: 12703204
[No Abstract] [Full Text] [Related]
15. Therapeutic efficacy of prenylation inhibitors in the treatment of myeloid leukemia.
Morgan MA; Ganser A; Reuter CW
Leukemia; 2003 Aug; 17(8):1482-98. PubMed ID: 12886235
[TBL] [Abstract][Full Text] [Related]
16. Protein farnesylation in mammalian cells: effects of farnesyltransferase inhibitors on cancer cells.
Tamanoi F; Gau CL; Jiang C; Edamatsu H; Kato-Stankiewicz J
Cell Mol Life Sci; 2001 Oct; 58(11):1636-49. PubMed ID: 11706990
[TBL] [Abstract][Full Text] [Related]
17. Combining prenylation inhibitors causes synergistic cytotoxicity, apoptosis and disruption of RAS-to-MAP kinase signalling in multiple myeloma cells.
Morgan MA; Sebil T; Aydilek E; Peest D; Ganser A; Reuter CW
Br J Haematol; 2005 Sep; 130(6):912-25. PubMed ID: 16156861
[TBL] [Abstract][Full Text] [Related]
18. Potent, highly selective, and non-thiol inhibitors of protein geranylgeranyltransferase-I.
Vasudevan A; Qian Y; Vogt A; Blaskovich MA; Ohkanda J; Sebti SM; Hamilton AD
J Med Chem; 1999 Apr; 42(8):1333-40. PubMed ID: 10212118
[TBL] [Abstract][Full Text] [Related]
19. Advances in the development of farnesyltransferase inhibitors: substrate recognition by protein farnesyltransferase.
Yang W; Del Villar K; Urano J; Mitsuzawa H; Tamanoi F
J Cell Biochem Suppl; 1997; 27():12-9. PubMed ID: 9591188
[TBL] [Abstract][Full Text] [Related]
20. Role of the carboxyterminal residue in peptide binding to protein farnesyltransferase and protein geranylgeranyltransferase.
Roskoski R; Ritchie P
Arch Biochem Biophys; 1998 Aug; 356(2):167-76. PubMed ID: 9705207
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
